|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNA-21 as a potential colon and rectal cancer biomarker显示文摘Colorectal cancer(CRC)is one of the most common malignant diseases worldwide and the prognosis is still poor although much progress has been achieved in recent years.In order to reduce CRC-related deaths,many studies are aimed at identifying novel screeningand prognosis-related biomarkers.MicroRNAs(miRNAs)are a class of 18-27-nucleotide single-stranded RNA molecules that regulate gene expression at the posttranscriptional level.It has been demonstrated that miRNAs regulate a variety of physiological functions,including development,cell differentiation,proliferation,and apoptosis.They play important roles in various physiologic and developmental processes and in the initiation and progression of various human cancers.It has been shown that miRNAs can critically regulate tumor cell gene expression,and evidence suggests that they may function as both oncogenes and tumor suppressor genes.In CRC,miRNAs-21 is one of the most important miRNAs and is rapidly emerging as a novel biomarker in CRC,with good potential as a diagnostic and therapeutic target.In this review,we summarize the latest research findings of the clinicopathological relevance of miRNAs-21 in CRC initiation,development,and progress,highlighting its potential diagnostic,prognostic,and therapeutic application,as well as discuss-ing future prospects. | Tao Li Mei Ha Leong Bruce Harms Gregory Kennedy Lin Chen | 2013 | World Journal of Gastroenterology2013，19，34： | 16 |
| 2 | Management of stage Ⅳ rectal cancer: Palliative options显示文摘Approximately 30% of patients with rectal cancer present with metastatic disease. Many of these patients have symptoms of bleeding or obstruction. Several treatment options are available to deal with the various complications that may afflict these patients. Endorectal stenting, laser ablation, and operative resection are a few of the options available to the patient with a malignant large bowel obstruction. A thorough understanding of treatment options will ensure the patient is offered the most effective therapy with the least amount of associated morbidity. In this review, we describe various options for palliation of symptoms in patients with metastatic rectal cancer. Additionally, we briefly discuss treatment for asymptomatic patients with metastatic disease. | Sean M Ronnekleiv-Kelly Gregory D Kennedy | 2011 | World Journal of Gastroenterology2011，17，7： | 5 |
| 3 | Bill Sugden Epstein-Barr virus provides a survival factor to Burkitt's lymphomas显示文摘 | Jun Komano | 2003 | Proc Natl Acad Sci USA2003，100，14： | 1 |
| 4 | Routine ileal intubation during screening colonoscopy: a useful maneuver?显示文摘 | Gregory Kennedy David Larson Bruce Wolff Desmond Winter Bret Petersen Mark Larson | 2008 | Surgical Endoscopy2008，，12： | 1 |
| 5 | Response surface optimization of corn stover pretreatment using dilute phosphoric acid for enzymatic hydrolysis and ethanol production显示文摘 | Ayse Avci Badal C. Saha Bruce S. Dien Gregory J. Kennedy Michael A. Cotta | 2012 | Bioresource Technology2012，，： | 1 |
| 6 | Detection and Localization of Intraepithelial Neoplasia and Invasive Carcinoma Using Fluorescence-Reflectance Bronchoscopy: An International, Multicenter Clinical Trial显示文摘 | Eric Edell Stephen Lam Harvey Pass York E. Miller Thomas Sutedja Timothy Kennedy Gregory Loewen Robert L. Keith | 2009 | Journal of Thoracic Oncology2009，，1： | 1 |
| 7 | Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials显示文摘 | Jonathan Emberson Kennedy R Lees Patrick Lyden Lisa Blackwell Gregory Albers Erich Bluhmki Thomas Brott Geoff Cohen Stephen Davis Geoffrey Donnan James Grotta George Howard Markku Kaste Masatoshi Koga Ruediger von Kummer Maarten Lansberg Richard I Lindley | 2014 | The Lancet . 2014 (9958)2014，，： | 1 |
| 8 | Comparable Postoperative Morbidity and Mortality After Laparoscopic and Open Emergent Restorative Colectomy: Outcomes From the ACS NSQIP显示文摘 | Nikiforos Ballian Natalie Weisensel Victoria Rajamanickam Eugene F. Foley Charles P. Heise Bruce A. Harms Gregory D. Kennedy | 2012 | World Journal of Surgery2012，，10： | 1 |
| 9 | Short-Term Outcomes after Laparoscopic-Assisted Proctectomy for Rectal Cancer: Results from the ACS NSQIP显示文摘 | David Yu Greenblatt Victoria Rajamanickam Andrew J. Pugely Charles P. Heise Eugene F. Foley Gregory D. Kennedy | 2011 | Journal of the American College of Surgeons2011，，： | 1 |
| 10 | Intestinal inflammation and the diet:Is food friend or foe?显示文摘Inflammatory bowel disease(IBD) is a chronic intestinal illness of autoimmune origin affecting millions across the globe. The most common subtypes include ulcerative colitis(UC) and Crohn's disease. While many medical treatments for IBD exist,none come without the risk of significant immunosuppression and in general do not have benign side effect profiles. Surgical intervention exists only as radical resection for medically refractory UC. There exists a dire need for novel treatments that target the inherent pathophysiologic disturbances of IBD,rather than global immune suppression. One avenue of investigation that could provide such an agent is the interaction between certain dietary elements and the aryl hydrocarbon receptor(AHR). The AHR is a cytosolic transcription factor with a rich history in environmental toxicant handling,however,recently a role has emerged for the AHR as a modulator of the gastrointestinal immune system. Studies have come to elucidate these effects to include the enhancement of Th cell subset differentiation,interactions between enteric flora and the luminal wall,and modulation of inflammatory interleukin and cytokine signaling. This review highlights advancements in our understanding of AHR activity in the digestive tract and how this stimulation may be wrought by certain dietary 'micronutriceuticals',namely indole-3-carbinol(I3C) and its derivatives. Greater clarity surrounding these dynamics could lead to a novel diet-derived agonist of the AHR which is not only non-toxic,but also efficacious in the amelioration of clinical IBD. | Bryant W Megna Patrick R Carney Gregory D Kennedy | 2016 | World Journal of Gastrointestinal Surgery2016，8，2： | 1 |
| 11 | Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials显示文摘 | Kennedy R Lees Erich Bluhmki Rüdiger von Kummer Thomas G Brott Danilo Toni James C Grotta Gregory W Albers Markku Kaste John R Marler Scott A Hamilton Barbara C Tilley Stephen M Davis Geoffrey A Donnan Werner Hacke | 2010 | The Lancet2010，，9727： | 1 |
| 12 | Dilute sulfuric acid pretreatment of corn stover for enzymatic hydrolysis and efficient ethanol production by recombinant Escherichia coli FBR5 without detoxification显示文摘 | Ayse Avci Badal C. Saha Gregory J. Kennedy Michael A. Cotta | 2013 | Bioresource Technology2013，，： | 1 |
| 13 | Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials显示文摘 | Kennedy R Lees Erich Bluhmki Rüdiger von Kummer Thomas G Brott Danilo Toni James C Grotta Gregory W Albers Markku Kaste John R Marler Scott A Hamilton Barbara C Tilley Stephen M Davis Geoffrey A Donnan Werner Hacke | 2010 | The Lancet2010，，9727： | 1 |
| 14 | Relationships of dead wood patterns with biophysical characteristics and ownership according to scale in Coastal Oregon, USA显示文摘 | Kennedy R Spies T Gregory M | 2008 | Landscape Ecology2008，23，1： | 1 |
| 15 | Optimizing surgical care of colon cancer in the older adult population显示文摘 | Gregory D Kennedy Victoria Rajamanickam Erin S O'connor | 2011 | Annals of Surgery2011，253，3： | 1 |
| 16 | The Diagnosis of Diverticulitis in Outpatients: On What Evidence?显示文摘 | Erin S. O’Connor Glen Leverson Gregory Kennedy Charles P. Heise | 2010 | Journal of Gastrointestinal Surgery2010，，2： | 1 |
| 17 | 急性卒中影像学研究路径图Ⅱ显示文摘卒中影像学研究组(StrokeImagingResearchGroup,STIR)、美国神经放射学学会和美国神经放射学学会基金会在过去1年多的时间时举办了一系列的工作会议,最后一次会议于2013年3月9日至10日在华盛顿召开的卒中治疗专业学术圆桌会议(Stroke Treatment Academy Industry Roundtable,STAIR)期间举行。 | Max Wintermark Gregory W. Albers Joseph P. Broderick Andrew M. Demchuk Jochen B. Fiebach Jens Fiehler James C. Grotta Gary Houser Tudor G. Jovin Kennedy R. Lees Michael H. Lev David S. Liebeskind Marie Luby Keith W. Muir Mark W. Parsons Rudiger von Kummer Joanna M. Wardlaw Ona Wu Albert J. Yoo Andrei V. Alexandrov Jeffry R. Alger Richard I. Aviv Roland Bammer Jean-Claude Baron Fernando Calamante Bruce C.V. Campbell Trevor C. Carpenter Sφren Christensen William A. Copen Colin P. Derdeyn E. Clarke Haley Jr Pooja Khatri Kohsuke Kudo Maarten G. Lansberg Lawrence L. Latour Ting-Yim Lee Richard Leigh Weili Lin Patrick Lyden Grant Mair Bijoy IC Menon Patrik Michel Robert Mikulik Raul G. Nogueira Left φstergaard Salvador Pedraza Christian H. Riedel Howard A. Rowley Pina C. Sanelli Makoto Sasaki Jeffrey L. Saver Pamela W. Schaefer Peter D. Schellinger Georgios Tsivgoulis Lawrence R. Wechsler Philip M. White Greg Zaharchuk Osama O. Zaidat Stephen M. Davis Geoffrey A. Donnan Anthony J. Furlan Werner Hacke Dong-Wha Kang Chelsea Kidw ell Vincent N. Thijs Gotz Thomalla Steven J. Warach 严晓铭 刘牧 张晶晶 柯开富 | 2014 | 国际脑血管病杂志2014，22，2： | 0 |
| 18 | 碳酸氢钠预防造影剂肾病——一项随机对照研究显示文摘背景:造影剂肾病仍是放射影像学检查的一种常见并发症。在动物急性缺血性肾衰竭模型中,预先使用碳酸氢钠比氯化钠的肾脏保护作用更佳。缺血和造影剂引发的急性肾衰竭均被认为是自由基损伤所致。但是,在人或动物至今尚无评价碳酸氢钠预防造影剂肾病有效性的研究。
目的:在使用放射性造影剂前后用碳酸氢钠或氯化钠进行预防性水化,比较二者的有效性。
设计、地点和病人:一项于2002年9月16日至2003年6月17日进行的前瞻性、单中心、随机试验。119例血清肌酐稳定在≥1.1mg/dL(t≥97.2μmol/L)水平的病人,在应用碘帕醇(370mg碘/mL)造影前后,随机接受了氯化钠静脉滴注(n=59)或碳酸氢钠静脉滴注(n=60),剂量均为154mEq/L。在造影前及造影后第1、2天进行了血清肌酐检测。
干预:病人接受154mEq/L的氯化钠或碳酸氢钠,造影前以每小时3mL/kg的速度静脉滴注1小时,造影后以每小时1mL/kg的速度滴注上述药物6小时。
主要观察指标:造影剂肾病,其定义为在造影后2天内血清肌酐升高tμ25%。
结果:两组病人在年龄、性别、糖尿病发生、种族以及造影剂用量方面无显著差异。碳酸氢钠治疗组病人基线血清肌酐水平稍高于氯化钠治疗组,但亦无显著差异(氯化钠组均值[sD]为1.71[0.42]mg/dL[151.2{37.1}μmol/L],碳酸氢钠组为1.89[0.69]mg/dL[167.1{61.0}μmol/L];P=0.09)。氯化钠组8例(13.6%),发生造影剂肾病一级终点,而碳酸氢钠组仅1例(1.7%)(均值差别,11.9%;95%可信区间[CI],2.6%~21.2%;P=0.02)。随后,又对191例符合研究纳入标准的病人给予了碳酸氢钠治疗并进行随访登记,结果有3例出现了造影剂肾病(1.6%;95%CI,0%~3.4%)。
结论:对于造影剂引发的肾衰竭,在造影前采用碳酸氢钠进行水化治疗比采用氯化钠水化治疗更为有效。 | Gregory J. Merten, MD W. Patrick Burgess, MD,PhD 1 Lee V. Gray,MD Jeremiah H. Holleman, MD Timothy S. Roush, MD Gien J. Kowalchuk, MD Robert M. Bersin, MD Arl Van Moore,MD Charles A. Simonton Ⅲ, MD Robert A. Rittase, PharmD H. James Norton,PhD Thomas P. Kennedy, MD, MPH 罗洋(译) 谌贻璞(校) | 2005 | 美国医学会杂志(中文版)2005，24，6： | 0 |
| 19 | Resolving the Mortierellaceae phylogeny through synthesis of multi-gene phylogenetics and phylogenomics显示文摘Early efforts to classify Mortierellaceae were based on macro-and micromorphology,but sequencing and phylogenetic studies with ribosomal DNA(rDNA)markers have demonstrated conflicting taxonomic groupings and polyphyletic genera.Although some taxonomic confusion in the family has been clarified,rDNA data alone is unable to resolve higher level phylogenetic relationships within Mortierellaceae.In this study,we applied two parallel approaches to resolve the Mortierel-laceae phylogeny:low coverage genome(LCG)sequencing and high-throughput,multiplexed targeted amplicon sequenc-ing to generate sequence data for multi-gene phylogenetics.We then combined our datasets to provide a well-supported genome-based phylogeny having broad sampling depth from the amplicon dataset.Resolving the Mortierellaceae phylogeny into monophyletic genera resulted in 13 genera,7 of which are newly proposed.Low-coverage genome sequencing proved to be a relatively cost-effective means of generating a high-confidence phylogeny.The multi-gene phylogenetics approach enabled much greater sampling depth and breadth than the LCG approach,but has limitations too.We present this work to resolve some of the taxonomic confusion and provide a genus-level framework to empower future studies on Mortierellaceae diversity and evolution. | Natalie Vandepol Julian Liber Alessandro Desirò Hyunsoo Na Megan Kennedy Kerrie Barry Igor V.Grigoriev Andrew N.Miller Kerry O’Donnell Jason E.Stajich Gregory Bonito | 2020 | Fungal Diversity2020，，5： | 0 |
| 20 | Outcomes of colon self-expandable metal stents for malignant vs benign indications at a tertiary care center and review of literature显示文摘BACKGROUND Endoscopic placement of a self-expandable metal stent(SEMS)is a minimally invasive treatment for use in malignant and benign colonic obstruction.However,their widespread use is still limited with a nationwide analysis showing only 5.4%of patients with colon obstruction undergoing stent placement.This underutilization could be due to perceived increase risk of complications with stent placement.AIM To review long-and short-term clinical success of SEMS use for colonic obstruction at our center.METHODS We retrospectively reviewed all the patients who underwent colonic SEMS placement over aeighteen year period (August 2004 through August 2022) at our academic center. Demographicsincluding age, gender, indication (malignant and benign), technical success, clinical success,complications (perforation, stent migration), mortality, and outcomes were recorded.RESULTSSixty three patients underwent colon SEMS over an 18-year period. Fifty-five cases were formalignant indications, 8 were for benign conditions. The benign strictures included diverticulardisease stricturing (n = 4), fistula closure (n = 2), extrinsic fibroid compression (n = 1), and ischemicstricture (n = 1). Forty-three of the malignant cases were due to intrinsic obstruction from primaryor recurrent colon cancer;12 were from extrinsic compression. Fifty-four strictures occurred on theleft side, 3 occurred on the right and the rest in transverse colon. The total malignant case (n = 55)procedural success rate was 95% vs 100% for benign cases (P = 1.0, NS). Overall complication ratewas significantly higher for benign group: Four complications were observed in the malignantgroup (stent migration, restenosis) vs 2 of 8 (25%) for benign obstruction (1-perforation, 1-stentmigration) (P = 0.02). When stratifying complications of perforation and stent migration there wasno significant difference between the two groups (P = 0.14, NS).CONCLUSIONColon SEMS remains a worthwhile option for colonic obstruction related to malignancy and has ahigh procedural and clinical success rate. Benign indications for SEMS placement appear to havesimilar success to malignant. While there appears to be a higher overall complication rate inbenign cases, our study is limited by sample size. When evaluating for perforation alone theredoes not appear to be any significant difference between the two groups. SEMS placement may bea practical option for indications other that malignant obstruction. Interventional endoscopistsshould be aware and discuss the risk for complications in setting of benign conditions. Indicationsin these cases should be discussed in a multi-disciplinary fashion with colorectal surgery. | Saqib Walayat Andrew J Johannes Mark Benson Eric Nelsen Ahmed Akhter Gregory Kennedy Anurag Soni Mark Reichelderfer Patrick Pfau Deepak Gopal | 2023 | World Journal of Gastrointestinal Endoscopy2023，15，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员